1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway

British Journal of Pharmacology

Volumn 152, Issue 2, 2007, Pages 230-239

  Chlopicki, S ^a   Swies, J ^a   Mogielnicki, A ^b   Buczko, W ^b   Bartus, M ^a   Lomnicka, M ^a   Adamus, J ^c   Gebicki, J ^c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

1 methylnicotinamide; COX 2; PGI 2; Platelets; Thrombolysis; Thrombosis

Indexed keywords

1 METHYLNICOTINAMIDE; 6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CYCLOOXYGENASE 2; DEXAMETHASONE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NICOTINAMIDE; NICOTINAMIDE METHYLTRANSFERASE; NICOTINIC ACID; PROSTACYCLIN; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; EXTRACORPOREAL CIRCULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VASODILATATION; VEIN THROMBOSIS;

ANIMALS; AORTA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; EPOPROSTENOL; FIBRINOLYTIC AGENTS; HYPERTENSION; LACTONES; MALE; MESENTERIC ARTERIES; NIACINAMIDE; PLATELET AGGREGATION; PROSTAGLANDINS; RATS; RATS, WISTAR; SULFONES; VASODILATION; VENOUS THROMBOSIS;

EID: 34948823247     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707383     Document Type: Article

References (39)

1. Aoyama K, Matsubara K, Okada K, Fukushima S, Shimizu K, Yamaguchi S et al. (2000). N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test. J Neural Transm 107: 985-995.
2. Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM et al. (2005). GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 115: 3634-3640.
3. Bieganowski P, Brenner C (2004). Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117: 495-502.
4. Bieron K, Swies J, Kostka-Trabka E, Gryglewski RJ (1998). Thrombolytic and antiplatelet action of xanthinol nicotinate (Sadamin): possible mechanisms. J Physiol Pharmacol 49: 241-249.
5. Chong ZZ, Lin SH, Maiese K (2002). Nicotinamidemodulates mitochondrial membrane potential and cysteine protease activity during cerebral vascular endothelial cell injury. J Vasc Res 39: 131-147.
6. Cylwik D, Mogielnicki A, Kramkowski K, Stokowski J, Buczko W (2004). Antithrombotic effect of L-arginine in hypertensive rats. J Physiol Pharmacol 55: 563-574.
7. Declercq V, Yeganeh B, Moshtaghi-Kashanian GR, Khademi H, Bahadori B, Moghadasian MH (2005). Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice. J Cardiovasc Pharmacol 46: 18-24.
8. + pathway metabolites as putative biomarkers and predictors of peroxisome proliferation. Arch Toxicol 79: 208-223.
9. Dembinska-Kiec A, Korbut R, Bieron K, Kostka-Trabka E, Gryglewski RJ (1983). Beta-Pyridylcarbinol (Ronicol) releases a prostacyclin-like substance into arterial blood of patients with arteriosclerosis obliterans. Pharmacol Res Commun 15: 377-385.
10. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ (2001). Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108: 585-590.
11. FitzGerald GA, Austin S, Egan K, Cheng Y, Pratico D (2000). Cyclooxygenase products and atherothrombosis. Ann Med 32 (Suppl 1): 21-26.
12. Frein D, Schildknecht S, Bachschmid M, Ullrich V (2005). Redox regulation: a new challenge for pharmacology. Biochem Pharmacol 70: 811-823.
13. Gebicki J, Sysa-Jedrzejowska A, Adamus J, Wozniacka A, Rybak M, Zielonka J (2003). 1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin. Pol J Pharmacol 55: 109-112.
14. Gosteli J (2005). Nicotinamide trials in diabetes intervention. Does a metabolite provide benefit? Med Hypotheses 64: 1062-1063.
15. Grosser T, Fries S, FitzGerald GA (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4-15.
16. Grudzinski S (1962). Preparation of N-methyl-2-pyridone-3-carboxamide. Roczniki Chemii 36: 1705-1708.
17. Gryglewski RJ (1980). Prostaglandins, platelets, and atherosclerosis. CRC Crit Rev Biochem 7: 291-338.
18. Gryglewski RJ, Moncada S, Palmer RM (1986). Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol 87: 685-694.
19. Gryglewski RJ, Uracz W, Swies J, Chlopicki S, Marcinkiewicz E, Lomnicka M et al. (2001). Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins. Ann N Y Acad Sci 947: 229-245.
20. Gupte SA, Arshad M, Viola S, Kaminski PM, Ungvari Z, Rabbani G et al. (2003). Pentose phosphate pathway coordinates multiple redox-controlled relaxing mechanisms in bovine coronary arteries. Am J Physiol Heart Circ Physiol 285: H2316-H2326.
21. Hennan JK, Hong TT, Willens DE, Driscoll EM, Giboulot TA, Lucchesi BR (2002). Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796. Br J Pharmacol 136: 927-937.
22. Maiese K, Chong ZZ (2003). Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol Sci 24: 228-232.
23. Maiza A, Waldek S, Ballardie FW, Daley-Yates PT (1992). Estimation of renal tubular secretion in man, in health and disease, using endogenous N-1-methylnicotinamide. Nephron 60: 12-16.
24. Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W (2005). Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 93: 1069-1076.
25. Ohta S, Nakamuta M, Fukushima M, Kohjima M, Kotoh K, Enjoji M et al. (2005). Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates concanavalin A-induced liver injury in mice. Liver Int 25: 1061-1068.
26. Pawlak R, Chabielska E, Buczko W (1996). Antithrombotic effect of enalapril, an angiotensin-converting enzyme inhibitor, on venous thrombosis in rats. Pol J Pharmacol 48: 117-120.
27. Pike NB (2005). Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest 115: 3400-3403.
28. Pumpo R, Sarnelli G, Spinella A, Budillon G, Cuomo R (2001). The metabolism of nicotinamide in human liver cirrhosis: a study on N-methylnicotinamide and 2-pyridone-5-carboxamide production. Am J Gastroenterol 96: 1183-1187.
29. Satoh T, Ishikawa Y, Kataoka Y, Cui Y, Yanase H, Kato K et al. (1999). CNS-specific prostacyclin ligands as neuronal survival-promoting factors in the brain. Eur J Neurosci 11: 3115-3124.
30. Schumacher WA, Steinbacher TE, Heran CL, Megill JR, Durham SK (1993). Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. Thromb Haemost 69: 509-514.
31. Shaw EN (1961). Quaternary pyridinium compounds. In: E Klingsberg (ed). Pyridine Its Derivatives. Interscience Publishers: New York, pp 1-31.
32. Swies J, Dabrowski L (1984). Release of disaggregatory prostanoids into circulation by nicotinic alcohol, nicotinic acid and nicotinamide. Pol J Pharmacol 36: 653-657.
33. Tanimori S, Ohta T, Kirihata M (2002). An efficient chemical synthesis of nicotinamide riboside (NAR) and analogues. Bioorg Med Chem Lett 12: 1135-1137.
34. Ungerstedt JS, Heimersson K, Soderstrom T, Hansson M (2003). Nicotinamide inhibits endotoxin-induced monocyte tissue factor expression. J Thromb Haemost 1: 2554-2560.
35. Vivian VM, Chaloupka MM, Reynolds MS (1958). Some aspects of tryptophan metabolism in human subjects. I. Nitrogen balances, blood pyridine nucleotides and urinary excretion of N1-methylnicotinamide and N1-methyl-2-pyridone-5- carboxamide on a low-niacin diet. J Nutr 66: 587-598.
36. Wise H, Jones RL (1996). Focus on prostacyclin and its novel mimetics. Trends Pharmacol Sci 17: 17-21.
37. Wojewodzka-Zelezniakowicz M, Chabielska E, Mogielnicki A, Kramkowski K, Karp A, Opadczuk A et al. (2006). Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats. J Physiol Pharmacol 57: 231-245.
38. Wozniacka A, Wieczorkowska M, Gebicki J, Sysa-Jedrzejowska A (2005). Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clin Exp Dermatol 30: 632-635.
39. Yan L, Otterness DM, Weinshilboum RM (1999). Human nicotinamide N-methyltransferase pharmacogenetics: gene sequence analysis and promoter characterization. Pharmacogenetics 9: 307-316.